India's NexCAR19 CAR-T Cell Therapy Receives Market Authorization
Recently, India's Central Drugs Standard Control Organisation (CDSCO) has granted market authorization for NexCAR19, the nation's first CAR-T cell therapy, marking a significant milestone in cancer treatment.
Key Points
- CAR-T therapy modifies T-cells, turning them into potent cancer fighters, offering a revolutionary approach to cancer treatment.
- Designed for B-cell lymphomas, NexCAR19 provides potential lifelong benefits and a one-time transformative therapy for non-responsive cancer patients.
- The patient's journey involves a doctor's prescription, blood donation, genetic modification of T-cells in the lab, and reinfusion within 7-10 days.
Effectiveness Compared to Other Treatments
- Contrast with chemotherapy and immunotherapy, emphasizing CAR-T's potential for a cure and ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content
Already a Member? Login here
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material since 2018 of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Science & Technology
- 1 Brain-Computer Interface to Restore Natural Speech
- 2 Neuralink to Implant 'Blindsight' Chip in First Human by 2025
- 3 Unexpected Atmospheric Gas on Exoplanet K2-18b
- 4 India Signs Deal with France for 26 Rafale-Marine Fighter Jets
- 5 SpaceX Launches Historic Fram2 Mission
- 6 Indian Army Inducts Indigenous FPV Drones
- 7 India’s First Prototype Fast Breeder Reactor Set for Commissioning in 2025
- 8 Blood Test for Cervical Cancer Monitoring
- 9 Google Launches Ironwood: 7th-Generation TPU for AI Workloads
- 10 QpiAI-Indus Quantum Computer